On March 15th, China Biopharmaceuticals officially released their performance report for last year. The income of Zhongsheng Pharmaceutical last year has increased by more than four times compared with that of 22. This increase in net profit has been higher than the recent income growth of major pharmaceutical companies. The main reason is that the sales of vaccines in COVID-19 have greatly improved the performance. Last year, they reached a cooperation with Kexing, and obtained part of the equity of Kexing. Moreover, the sales of related COVID-19 vaccines have spread all over the world, which has also made great contributions to their profit growth.
according to their financial report for 221, it shows that their main business segment income last year mainly came from their new products, which performed very well on the market, and the sales of over 1 million products have reached 5 of them. Especially anti-tumor drugs are more. Zhongsheng Pharmaceutical has promoted the research and development of a variety of anti-tumor drugs, which are also well targeted. At the same time, it has reached an agreement with the National Medical Insurance Bureau, and all related drugs are included in medical insurance, which can provide good medical effects for our patients. Their research and development platform in China local enterprises can rank among the top three.
They invested heavily in pharmaceutical research and development, mainly in Zhongsheng Pharmaceutical last year. Last year, * * built two academician workstations and a national enterprise technology center. Even in the middle of last year, they used AI drug research and development to cooperate with the pharmaceutical giants in the world, which improved the manufacturing capacity of small molecular drugs from the source, more able to meet the clinical medical needs, and can be treated in combination with the differentiation of patients.
In addition, Zhongsheng Pharmaceutical also made a lot of contributions to our country last year. They took the initiative to assume the due responsibilities of enterprises and actively participated in various public welfare undertakings, such as fighting the epidemic, fighting floods and providing disaster relief, and so on. Moreover, when the epidemic broke out in Hong Kong this year, they also sent special medical teams, donated quite a few COVID-19 detection reagents and donated a lot of epidemic prevention materials, which made outstanding contributions to the epidemic prevention control in Hong Kong.